Research · Sep 3, 2026
[ASND] Ascendis Pharma Thesis 2026: Yorvipath Launch Drives Path to Five Hundred Million Free Cash
Ascendis Pharma A/S FY25 revenue $692M (+90% YoY) reflecting Yorvipath + Skytrofa commercial ramp; op income -$131M (vs -$279M FY24, narrowing); NI -$219M (vs -$378M FY24); EPS -$3.62 (vs -$6.53). FCF $44M (positive, vs -$308M FY24 — major inflection). Yorvipath: Q4 2025 revenue €187M / full-year 2025 revenue €477M. US: over 5,300 patients prescribed by ~2,400 providers; less than 5% of US patients on treatment; insurance approval rate ~70%; majority approvals within 8 weeks. Outside US: 30+ countries; full commercial reimbursement in 4 Europe direct + 2 international markets; 10 new country launches in 2026. Skytrofa: Q4 2025 revenue €53M / full-year €206M. Market share ~7% in US. Initiated Phase III basket trial for additional growth hormone indications. TransCon CNP: pivotal trial showed significant improvement vs placebo; NDA for children with achondroplasia in US under review; MAA in EU underway; Phase II combination trial data shows dual therapy potential with TransCon Growth Hormone. Partnership with Novo Nordisk for once-monthly TransCon semaglutide. Total debt $871M (+2%). FY26 guide: continued strong Yorvipath growth (steady patient uptake with seasonality); Skytrofa seasonal pattern; aim to achieve operating cash flow of ~€500M in 2026; at least €5B in annual product revenue by 2030; TransCon CNP US approval excluded from 2026 outlook (upside). Risks: Yorvipath commercial execution, market dynamics + competition (Crinetics, Amolyt / AstraZeneca), TransCon CNP regulatory timing, Skytrofa competition (Novo Sogroya, Pfizer Genotropin, Lilly Humatrope), FX (EUR/USD).